The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study

The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study

Background/Aim: Radium-223 dichloride (<sup>223</sup>RaCl<sub>2</sub>) represents a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients dealing with symptomatic bone metastases. The identification of baseline variables potentially affecting...

Full description

Bibliographic Details
Main Authors:	Maria Silvia De Feo, Viviana Frantellizzi, Matteo Bauckneht, Alessio Farcomeni, Luca Filippi, Elisa Lodi Rizzini, Valentina Lavelli, Maria Lina Stazza, Tania Di Raimondo, Giuseppe Fornarini, Sara Elena Rebuzzi, Mammini Filippo, Paolo Mammucci, Andrea Marongiu, Fabio Monari, Giuseppe Rubini, Angela Spanu, Giuseppe De Vincentis
Format:	Article
Language:	English
Published:	MDPI AG 2023-04-01
Series:	Biomedicines
Subjects:	mCRPC DASciS software bone scan index radium-223 overall survival bone metastasis
Online Access:	https://www.mdpi.com/2227-9059/11/4/1103

Similar Items

Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment
by: Frantellizzi Viviana, et al.
Published: (2019-12-01)

Large Italian Multicenter Study on Prognostic Value of Baselines Variables in mCRPC Patients Treated with <sup>223</sup>RaCl<sub>2</sub>: Ten Years of Clinical Experience
by: Maria Silvia De Feo, et al.
Published: (2025-01-01)

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
by: H. Taghizadeh, et al.
Published: (2019-11-01)

Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE
by: Daniele Santini, et al.
Published: (2021-02-01)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Iván Henríquez, et al.
Published: (2021-09-01)

Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT
by: Florian Rosar, et al.
Published: (2024-05-01)

Prostate-speciﬁc antigen response after Abiraterone treatment in mCRPC: PSA as a predictor of overall survival
by: Alexandre Mendonça Macedo, et al.
Published: (2023-02-01)

Real-world efficacy and safety of combined first-line treatment with PARP inhibitors and novel hormonal therapy in mCRPC patients with HRR gene mutations
by: Andong Guo, et al.
Published: (2024-12-01)

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T
by: Julia Brosch-Lenz, et al.
Published: (2021-03-01)

Assessment of Skeletal Tumor Load in Metastasized Castration-Resistant Prostate Cancer Patients: A Review of Available Methods and an Overview on Future Perspectives
by: Francesco Fiz, et al.
Published: (2018-07-01)

Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients
by: Florian Rosar, et al.
Published: (2020-05-01)

Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study
by: Sijin Chen, et al.
Published: (2024-08-01)

Total Tumor Volume on <sup>18</sup>F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with <sup>225</sup>Ac-PSMA-I&T
by: Lena M. Unterrainer, et al.
Published: (2022-04-01)

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
by: Axel Heidenreich, et al.
Published: (2019-01-01)

Management of elderly mCRPC patients
by: Seiichiro Ozono
Published: (2015-12-01)

Skeletal-Related Events (SRE) in Prostate Cancer: A Report of Two Cases
by: Anak Agung Ngurah Oka Diatmika, et al.
Published: (2021-09-01)

Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval
by: Amir Karimzadeh, et al.
Published: (2024-10-01)

Development of [<sup>225</sup>Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
by: Eline L. Hooijman, et al.
Published: (2021-05-01)

Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey
by: Daniel J. George, et al.
Published: (2023-03-01)

3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT
by: Astrid Gosewisch, et al.
Published: (2019-08-01)

Withdrawal syndrome and PSA flare in the management of mCRPC with abiraterone
by: Po Hui Chiang
Published: (2015-12-01)

Skeleton Segmentation on Bone Scintigraphy for BSI Computation
by: Po-Nien Yu, et al.
Published: (2023-07-01)

Abscopal Effect on Bone Metastases from Solid Tumors: A Systematic Review and Retrospective Analysis of Challenge within a Challenge
by: Miriam Tomaciello, et al.
Published: (2023-04-01)

Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
by: Murali Kesavan, et al.
Published: (2021-03-01)

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends
by: Thapa B, et al.
Published: (2024-09-01)

Comparison of metastatic castration-resistant prostate cancer in bone with other sites: clinical characteristics, molecular features and immune status
by: Zhengquan Xu, et al.
Published: (2021-03-01)

Prognostic value of the bone scan index in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
by: Hualin Song, et al.
Published: (2020-03-01)

Response Assessment and Prediction of Progression-Free Survival by <sup>68</sup>Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Fadi Khreish, et al.
Published: (2021-07-01)

Establishment of the Protocol of Intramuscular 223RaCl2 Injection and the Corresponding Evaluation on Feasibility and Safety
by: LI Xiaohong;ZUO Changjing;LI Xiao
Published: (2023-08-01)

Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?
by: Martina Di Franco, et al.
Published: (2024-10-01)

Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race
by: Bilen MA, et al.
Published: (2024-09-01)

PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC?
by: Abhay Singh Gaur
Published: (2022-01-01)

Natural Compounds and Histone Deacetylase Inhibitors: A Combined Approach Against mCRPC Cells
by: Janiah Alimudin, et al.
Published: (2025-01-01)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model
by: Nourridine Siewe, et al.
Published: (2022-01-01)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.
by: Nourridine Siewe, et al.
Published: (2022-01-01)

The Many Faces Of mCRPC- Assessing Patient Profiles and Tailoring Treatment in a Changing Landscape
by: Manfred Wirth, et al.
Published: (2014-05-01)

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients With mCRPC Treated With Abiraterone
by: Cristian Lolli, et al.
Published: (2016-10-01)

Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.
by: Carlo Cattrini, et al.
Published: (2020-01-01)

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
by: Joshua P. Schiff, et al.
Published: (2019-05-01)

Therapy Management of Metastatic Prostate Carcinoma in General Practice
by: Alexander Meisel
Published: (2019-09-01)